KRP-203

a synthetic immunosuppressant that prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts; structure in first source

Also Known As:

2-amino-2-(2-(4-(3-benzyloxyphenylthio)-2-chlorophenyl)ethyl)-1,3-propanediol hydrochloride

Networked: 8 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfhydryl Compounds: 4168
    - KRP-203: 8

Experts

1.	Yasue, Tokutaro: 4 articles (01/2008 - 01/2005)
2.	Kobayashi, Eiji: 4 articles (09/2007 - 01/2005)
3.	Murakami, Takashi: 4 articles (09/2007 - 01/2005)
4.	Takahashi, Masafumi: 4 articles (09/2007 - 01/2005)
5.	Kinoshita, Miki: 2 articles (01/2008 - 09/2006)
6.	Ikeda, Uichi: 2 articles (09/2007 - 03/2006)
7.	Ise, Hirohiko: 2 articles (09/2007 - 03/2006)
8.	Kuriyama, Kazuhiko: 2 articles (09/2007 - 01/2005)
9.	Morimoto, Hajime: 2 articles (09/2007 - 03/2006)
10.	Fujishiro, Jun: 2 articles (09/2006 - 03/2006)

Related Diseases

1.	Bradycardia 01/18/2005 - "These findings demonstrated that KRP-203 prolonged skin and heart allograft survival and significantly attenuated chronic rejection and bradycardia as an adverse effect. " 09/27/2006 - "The selectivity of KRP-203 for S1P1 reduces the risk of bradycardia, and the combination therapy of KRP-203 with CsA represents a safe and effective strategy for use in renal transplantation." 01/18/2005 - "KRP-203 had less of a tendency to cause bradycardia than FTY720. "
2.	Body Weight (Weight, Body) 01/01/2008 - "KRP-203 treatment was effective in preventing body weight loss in the IL-10(-/-) colitis model. " 09/28/2007 - "KRP-203 significantly attenuated the inflammation area, heart weight/body weight ratio, and left ventricular function. "
3.	Atherosclerosis 07/01/2013 - "KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice."
4.	Myocarditis (Carditis) 09/28/2007 - "We investigated the efficacy of KRP-203 in the treatment of rat experimental autoimmune myocarditis. " 09/28/2007 - "These results demonstrate the therapeutic potential of KRP-203 for the treatment of human myocarditis and provide new insights into the pathogenesis of this disease." 09/28/2007 - "A novel sphingosine-1-phosphate receptor agonist KRP-203 attenuates rat autoimmune myocarditis."
5.	Colitis 01/01/2008 - "Therefore, the possibility arises that KRP-203 plays a potential role in control of chronic colitis." 01/01/2008 - "KRP-203 was administered for 1 or 4 weeks to IL-10(-/-) mice with clinical signs of colitis. " 01/01/2008 - "KRP-203 treatment was effective in preventing body weight loss in the IL-10(-/-) colitis model. " 01/01/2008 - "KRP-203 significantly inhibits ongoing IL-10(-/-) colitis in part through decreasing the infiltration of lymphocytes at inflammatory sites and by blocking T-helper 1 cytokine production in the colonic mucosa. " 01/01/2008 - "We aimed to evaluate the efficacy and potency of KRP-203 on the treatment of chronic colitis in an interleukin (IL)-10 gene-deficient (IL-10(-/-)) mouse model. "

Related Drugs and Biologics

1.	Sphingosine-1-Phosphate Receptors
2.	oxidized low density lipoprotein
3.	siponimod
4.	ponesimod
5.	ceralifimod
6.	Transforming Growth Factor beta1 (TGF beta 1)
7.	Endothelin-1 (Endothelin 1)
8.	E-Selectin
9.	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
10.	Interleukin-8 (Interleukin 8)

Related Therapies and Procedures

1.	Kidney Transplantation
2.	Therapeutics
3.	Heart Transplantation (Grafting, Heart)